

ACTINOGEN MEDICAL LIMITED

APPENDIX 4 E

1. Company details

Name of entity

ACTINOGEN MEDICAL LIMITED

ABN or equivalent company reference

14 086 778 476

Financial year ended
(‘reporting period’)

30 June 2024

Financial year ended
(‘previous corresponding period’)

30 June 2023

2. Results for announcement to the market

	30/06/2024 \$	30/06/2023 \$	Change %	Amount change \$
Revenue from ordinary activities	291,021	366,654	-21%	(75,633)
Loss from ordinary activities after tax attributable to members	(13,044,282)	(10,752,270)	21%	(2,292,012)
Net loss for the period attributable to members	(13,044,282)	(10,752,270)	21%	(2,292,012)
Net tangible asset per share (a)	0.007	0.006		

(a) Includes right-of-use asset

3. Statement of Comprehensive Income

Refer to attached financial statements.

4. Statement of Financial Position

Refer to attached financial statements.

5. Statement of Cash Flows

Refer to attached financial statements.

6. Statement of Changes in Equity

Refer to attached financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of Dividend Reinvestment Plan

Not applicable.

9. Details of entities over which control has been gained or lost during the period

Not applicable.

10. Details of associates and joint venture entities

Not applicable.

11. Any other significant information needed by an investor to make an informed assessment of the Company’s financial performance and financial position

Refer to attached financial statements.

12. Foreign entities

Not applicable.

ACTINOGEN MEDICAL LIMITED

APPENDIX 4 E

13. Commentary on results and explanatory information

Actinogen Medical Limited ('the Company') incurred a net loss after tax for the financial year ended 30 June 2024 of \$13,044,282 (2023: \$10,752,270)

	Full year ended 30/06/2024	Full year ended 30/06/2023
	\$	\$
Interest revenue	291,021	366,654
Other income	9,931,504	4,887,935
Total revenue & other income	10,222,525	5,254,589
Research & development costs	(15,535,482)	(8,899,947)
Employment costs	(4,195,292)	(3,257,223)
Corporate & administration costs	(1,732,305)	(1,793,660)
Finance costs	(24,292)	(16,599)
Realised (loss) / unrealised gain on foreign currency	(55,189)	(117,172)
Share-based payment expenses	(1,307,416)	(1,516,650)
Amortisation expense	(313,602)	(312,746)
Depreciation expense (right-of-use asset)	(82,179)	(81,008)
Depreciation expense (office equipment)	(21,050)	(11,854)
Total expenses	(23,266,807)	(16,006,859)
Loss before income tax	(13,044,282)	(10,752,270)
Income tax expense	-	-
Loss for the year	(13,044,282)	(10,752,270)

The R&D tax rebate comprises an accrual of \$9,022,474 relating to the financial year ended 30 June 2024 plus \$909,030 relating to the prior year 30 June 2023 R&D tax rebate, which was an additional portion not recorded as a receivable as at 30 June 2023 but instead was recognised and recorded when received in the current year.

While all other expenditure remained comparable with the prior year, there was an increase in employment costs as a result of recruitment and salary increases, as well as various termination of employment and genuine redundancies that occurred during the year.

The Company's R&D trial activities during the year increased significantly as the XanaCIDD phase 2a cognitive impairment and depression trial ramped up to full enrolment, and as the XanaMIA phase 2b Alzheimer's disease trial was commenced.

For further information, refer to the Directors' Report and the Financial Statements.

14. Audit

This report is based on accounts which have been audited.

Dr Steven Gourlay
 Managing Director
 Sydney, New South Wales
 30 August 2024
 Authorised for release by the Board of Directors.